Comparing the current results to its competitors, Orgenesis Inc reported Revenue increase in the 3 quarter 2024 by 215.45 % year on year. The sales growth was above Orgenesis Inc 's competitors' average revenue growth of 63.97 %, achieved in the same quarter.
Orgenesis Inc 's Comment on Competition and Industry Peers
The biopharmaceutical industry, particularly the cell therapy sector, is highly competitive and demands continuous innovation and speed. Competitors include major multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, universities, and other research institutions. Many of these competitors possess substantially greater financial and technical resources, larger research and development teams, and experienced marketing and manufacturing organizations with established sales forces. Smaller or early-stage companies may also be significant competitors, especially through collaborations with larger, established companies. Currently, the company is not aware of any other entities pursuing a business model similar to its POCare Platform. However, competitors in the cell and gene therapy (CGT) field that are larger and better capitalized could adopt similar strategies and develop them more rapidly.
August 14, 2024
In a groundbreaking announcement that is set to reverberate through the healthcare industry, Orgenesis Inc. has forged a strategic partnership with the esteemed Harley Street Healthcare Group. This alliance aims to launch an innovative global longevity and wellness initiative, reflecting a robust commitment to advancing health and well-being in an era where wellness innovation is paramount.The partnership is not merely strategic in nature; it comes with a significant financial backing of up to $10 million over the next three years. This investment will bolster both Orgenesis and the newly created joint venture, affirming their dedication to developing cutting-edge solutions that address the evolving wellness...
April 10, 2024
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership to Revolutionize Cell and Gene TherapyOrmond Beach, Florida, and Germantown, Maryland - Germfree, a leading modular cleanroom infrastructure and services provider, has joined forces with Orgenesis Inc., a global leader in decentralizing cell and gene therapies (CGTs). Through an asset purchase and strategic partnership, the collaboration aims to advance Orgenesis therapeutic programs and its suite of product development and GMP cell processing services, with the ultimate goal of transforming the production of cell and gene therapies and making them more affordable and accessible to patients worldwide.Cell and gene therapies have gained...
Transmedics Group Inc operates on a business model focused on medical technology. They develop and commercialize portable systems to facilitate the transplantation of organs and tissues. Their innovative platforms provide organ preservation, transportation, and monitoring solutions, aiming to improve patient outcomes in organ transplantation procedures.
Sources:
Orgenesis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Orgenesis Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
